



## **DETECT Abstracts Selected for Oral Presentation at European Endometriosis Congress 2026**

**London, UK, 13 April 2026.** [Serac Healthcare Limited](#) (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that two abstracts on the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” imaging (DETECT) study, have been selected for oral presentation in the “Best Submitted Abstracts” sessions at the 8<sup>th</sup> [European Endometriosis Congress](#) taking place from 23<sup>rd</sup> to 25<sup>th</sup> April in Bologna, Italy.

[Dr Tatjana Gibbons](#), an investigator on the study from the [Nuffield Department of Women’s and Reproductive Health](#) at the [University of Oxford](#), will be presenting results from the study which aims to determine the feasibility of detecting endometriosis using <sup>99m</sup>Tc-maraciclatiside and single-photon emission computed tomography, in the following sessions:

**In vivo imaging of angiogenesis in endometriosis lesions:** 11.30-13.00 on 24/4/26 in Hall B; Best Submitted Abstracts Session

**DETECTION of SPE and extra-pelvic endometriosis with a 20-minute <sup>99m</sup>Tc-maraciclatiside imaging scan:** 11.30-13.30 on 25/4/2026 in HallB – Young Presenters EEL and ETIC Session; Best Submitted Abstracts Session

Initial findings have demonstrated a high correlation between locations of maraciclatiside uptake identified on SPECT-CT and laparoscopy across all types of endometriotic lesions, including superficial peritoneal endometriosis, which is not well visualised with existing non-invasive imaging techniques.

The study was led by [Professor Christian Becker](#), Co-Director of the Endometriosis CaRe Centre in Oxford, together with [Professor Krina Zondervan](#), Co-Director of the Endometriosis CaRe Centre and Head of Department at the Nuffield Department of Women’s and Reproductive Health, University of Oxford.

**-ENDS-**

**Maraciclatiside is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.**

**For more information, please contact:**

Serac Healthcare Ltd

[www.serachealthcare.com](http://www.serachealthcare.com)

David Hail, Chief Executive Officer

+44 (0)208 948 0000

[info@seraclifesciences.com](mailto:info@seraclifesciences.com)

Francetta Carr, Communications Director

+44 (0)7711 010820

[francettacarr@seraclifesciences.com](mailto:francettacarr@seraclifesciences.com)

## Notes to Editors

### About Serac Healthcare Ltd

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

### About <sup>99m</sup>Tc-maraciclatiside

<sup>99m</sup>Tc-maraciclatiside is a radio-labelled tracer which binds with high affinity to the cell adhesion protein  $\alpha_v\beta_3$  integrin and images angiogenesis (new blood vessel formation) which is known to be critical to the establishment and growth of endometriotic lesions.

### About the DETECT study

In the DETECT study, women with confirmed or suspected endometriosis who are due to undergo laparoscopy, a key-hole surgical procedure used to assess the organs in the abdomen and pelvis, are imaged with <sup>99m</sup>Tc-maraciclatiside before laparoscopic surgery. During surgery, tissue samples with identified endometriosis are collected and analysed to determine the presence of  $\alpha_v\beta_3$ . The laparoscopic and radiographic findings are compared to determine whether <sup>99m</sup>Tc-maraciclatiside holds potential as a novel, non-invasive method of detecting early-stage endometriosis.

The study is jointly sponsored by Oxford Endometriosis CaRe Centre and the Nuffield Department of Women's and Reproductive Health, Oxford University, and funded by Serac Healthcare Ltd who are providing the experimental imaging marker <sup>99m</sup>Tc-maraciclatiside. Further details are available on ClinicalTrials.gov [here](#).

**About the European Endometriosis Congress:** [www.eec2026.com](http://www.eec2026.com)